Biotech Financial Strategy: From Seed to Series A
A successful biotech financial strategy requires moving through an increasingly competitive funding landscape. Series A rounds typically range from $10M to $30M in exchange for 15-30% equity. Biotech venture investments will likely grow from $483 billion in 2024 to $546 billion by 2025, showing a remarkable 13% CAGR.
Getting Series A funding remains challenging for early-stage biotech companies. It now takes twice as long to secure committed capital. Founders often need hundreds of conversations before getting a yes. Some specialized sectors still draw major attention. Obesity-focused biotech investments soared to $900 million in 2024 from just $163 million in 2023 – a dramatic 550% increase.
This guide will help you understand the vital transition from seed to Series A funding for biotech startups. You’ll learn how investor expectations change, what milestones matter most, and ways to build operational readiness. These elements attract venture capitalists who take on riskier investments for potentially higher returns. This roadmap serves both first-time fundraisers and experienced founders as they move through the complex biotech financing world.
Understanding the Shift: From Seed to Series A
Image Source: Basel Area Business & Innovation
The path from seed to Series A marks a turning point in the biotech funding trip. We have a long way to go, but we can build on this progress as companies face new expectations and requirements. Let’s get into this transformation that decides which companies move forward and which get stuck in the biotech ecosystem.
How investor expectations evolve
Seed investors and Series A investors think differently about their investments. Seed investors look for ambitious 100X returns, knowing that just two or three companies in their portfolio of 20-50 investments will bring all their returns. Series A investors want 10-15X returns but expect fewer companies to fail.
This change in thinking shapes what matters to investors. Seed investors back potential – they invest in the founding team, concept, and sometimes a minimum viable product. Series A investors need solid proof that you can execute, including:
- Proven product-market fit
- Early revenue or strong user metrics
- A repeatable go-to-market strategy
- A flexible business model
- A strong, experienced leadership team
Series A investors dig deeper during due diligence and look closely at financial performance and market position. On top of that, it now takes twice as long to secure Series A commitments compared to previous years.
Why Series A is not just a bigger seed round
Biotech founders often think Series A funding is just seed funding on a larger scale. The reality shows a transformation from proving concepts to building flexible businesses.
Seed stage companies focus on scientific validation, early strategic collaborations, and regulatory planning. Series A investors want proof that you can deliver beyond the lab – showing that your technology works in real-life situations.
Biotech companies typically raise $10M to $30M for Series A funding in exchange for 15-30% equity. Unlike seed funding from angels and micro-VCs, institutional investors lead Series A rounds. They usually take board seats and help shape company strategy.
Key differences in funding goals
Each funding stage serves different purposes. Seed funding launches your startup, while Series A proves traction and grows operations.
Platform companies need to show Series A investors clear target indications with strong reasoning about unmet needs, competition, and platform-disease fit. They must also prove efficacy and safety in multiple animal models.
Asset-focused biotech companies raise Series A funding to support development candidates for lead programs. Their main goal focuses on completing IND-enabling studies and moving to clinical stages.
Biotech investors love innovative platform technologies. Series A funding rounds make up almost half of all biotech deals. This preference explains why $15 billion went to platform biotechs in 2022, which is a big deal as it means that it exceeded the $6.5 billion given to traditional asset-based biotechs.
Milestones to Hit Before Series A
Image Source: FasterCapital
Biotech startups need to show real progress beyond promising research to secure Series A funding. Getting this money depends on reaching specific goals in three areas.
Scientific and clinical progress
Biotech companies must move well beyond their original research to be ready for clinical trials. Series A investors want to see completed preclinical toxicology studies, clear manufacturing plans, and proper regulatory documentation. Therapeutic companies should verify their targets through mechanistic studies and show proof-of-concept data in animal models with early in vitro results. Most investors now look for drug programs that are close to human testing or already there.
Market validation and early traction
Product-market fit verification through adoption metrics and customer satisfaction is vital for Series A readiness. Platform companies should generate about $1M in yearly recurring revenue. SaaS/AI startups need to show adaptable revenue growth. Mutually beneficial alliances, letters of intent, or pilot programs help verify market interest effectively.
Regulatory planning and IP protection
Intellectual property remains a biotech startup’s most valuable asset. Strong IP needs broad, defensible patent protection that covers products, methods, and manufacturing processes. Companies that reach regulatory milestones get follow-on funding 40% faster than those without clear regulatory paths. A well-laid-out plan of key preclinical milestones—including target validation, lead optimization, and IND-enabling studies—helps line up resources properly.
Building Operational and Financial Readiness
Scientific breakthroughs alone won’t guarantee success in biotech financing. Your Series A valuation depends on having well-laid-out systems in place.
Structuring your cap table and financials
A well-organized cap table helps build investor confidence and makes due diligence easier. Note that founders should stick to common stock instead of preferred shares. This prevents any conflicts of interest. The standard vesting periods run 4-5 years with a one-year cliff. These reassure investors about your long-term commitment. You must file your 83b election within 30 days of stock purchase. This establishes a low cost basis and saves you tax dollars. Your financial records need to show detailed burn rates and runway projections clearly. They should also outline how you plan to use Series A capital.
Hiring beyond the founding team
Series A investors look beyond visionary founders. They want to see a company that can deliver results at scale. You need purpose-built teams that line up with specific value-inflection milestones. Your original focus should be on bringing in commercial/sales leaders and clinical experts. Each new hire should connect directly to your scientific progress and funding milestones. This ensures you have the right people at the right time—not before you need them.
Preparing for due diligence
Series A investors take a deep look at clinical, scientific, and legal aspects. So, you need an electronic data room with detailed documentation. This includes formation records, material contracts, financial statements, and employment agreements. Biotech companies must pay special attention to their clinical data packages. These should contain trial protocols, patient demographics, endpoints, and safety monitoring procedures. A full picture shows operational discipline and speeds up the funding process.
Crafting a Winning Series A Fundraising Strategy
Image Source: Mergers & Inquisitions
A successful Series A fundraising needs a targeted approach rather than a scattershot strategy. The median biotech Series A deal sizes have reached $58.70 million in 2024. This means founders need to position their companies strategically to stand out.
Identifying the right biotech investors
The biotech investment landscape has three distinct categories: biotech-focused VCs like Flagship Pioneering and Third Rock Ventures, corporate/pharma VCs such as Pfizer Ventures and Novartis Venture Fund, plus generalist firms including Andreessen Horowitz Bio+Health. Your target should be investors whose portfolio contains companies with similar regulatory timelines or commercialization strategies. Biotech VCs value introductions from entrepreneurs they already know.
Building relationships before the raise
Your relationships with potential Series A investors should start at least 6-9 months before you need capital. This timeline matters even more now that Series A closings typically take 12-18 months instead of the previous 12-month norm. Many founders find that securing Series A funding takes hundreds of investor conversations. DeepLook Medical’s CEO noted it took “hundreds of investor conversations and detailed due diligence” before closing their Series A.
Running a structured fundraising process
A well-organized data room should contain detailed documentation including financial projections, KPIs, and legal documents. Investors now want up-to-the-minute access to clinical, regulatory, and IP documentation before they consider term sheets. You can create competitive tension by approaching multiple investors at once—this helps maintain leverage during negotiations. Your clear message should show how the funding will help reach your next milestone, typically covering 18-24 months of operations.
Avoiding common fundraising mistakes
Never appear desperate for cash—unfavorable terms from the wrong investors create challenges during future rounds. The fundraising process typically takes 6 months and needs significant time commitment. Founders often underestimate their funding needs. You should secure enough capital to sustain growth for at least two years after Series A. Your pitch must include a clear go-to-market strategy and long-term profitability narrative.
Conclusion
The experience of getting biotech funding from seed to Series A stage requires strategic planning, operational excellence, and scientific credibility. The current funding landscape presents both the most important challenges and opportunities. Biotechs now take twice as long to secure commitments despite projected market growth to $546 billion by 2025.
Series A represents more than just capital – it marks a fundamental shift in investor expectations. Seed investors back potential with hopes for 100X returns. Series A backers want concrete evidence of execution capabilities, flexible business models, and clear paths to commercialization.
Biotech companies must hit specific scientific milestones to get Series A funding. These include preclinical toxicology studies and animal model proof-of-concept data. Market validation through partnerships or early revenue shows viability beyond the lab. A complete regulatory plan and strong IP protection create foundational value.
Strong operational readiness separates successful Series A candidates from others. Companies need clean cap tables, standard vesting periods, and transparent financials. Team expansion beyond founders signals growth capacity. Well-laid-out documentation speeds up due diligence.
The fundraising process needs careful planning. You should find investors that match your biotech category. Start building relationships 6-9 months before you need capital. Run a structured process with competitive tension between multiple investors. Never appear desperate during this experience – look for partnerships, not just money.
The seed-to-Series A transition marks a critical point. It separates ventures that survive from those ready to thrive. Companies that prepare well across scientific, operational, and strategic areas end up securing more than funding. They find the right partners for long-term success. The biotech funding space remains competitive. Those who master these basics will capitalize on biotech investment’s continued worldwide growth.
Key Takeaways
Transitioning from seed to Series A in biotech requires understanding fundamental shifts in investor expectations, achieving concrete milestones, and building operational excellence beyond scientific innovation.
• Series A investors seek execution proof, not just potential – They want 10-15X returns with concrete evidence of product-market fit, scalable business models, and experienced leadership teams, unlike seed investors who back 100X potential.
• Hit three critical milestone categories before fundraising – Complete preclinical studies and regulatory documentation, demonstrate market validation through partnerships or revenue, and secure robust IP protection with clear regulatory pathways.
• Build operational readiness with clean financials and strategic hiring – Structure transparent cap tables with proper vesting, maintain detailed burn rate projections, and hire purpose-built teams aligned to specific value-inflection milestones.
• Start investor relationships 6-9 months before needing capital – Target biotech-focused VCs whose portfolios align with your strategy, as Series A rounds now take 12-18 months to close and require hundreds of investor conversations.
• Raise sufficient capital for 18-24 months of operations – Avoid appearing desperate by securing enough funding to reach your next major milestone, as fundraising typically consumes 6 months and is extremely time-intensive.
With biotech investments projected to reach $546 billion by 2025, companies that master these fundamentals position themselves to capitalize on continued market growth while securing the right strategic partners for long-term success.
FAQs
Q1. What is the typical range for a Series A funding round in biotech? Series A funding for biotech companies typically ranges from $10 million to $30 million, usually in exchange for 15-30% equity in the company.
Q2. How long does it typically take to secure Series A funding in the current biotech market? Currently, it’s taking about twice as long to secure Series A commitments compared to previous years. The process now often takes 12-18 months, up from the previous norm of around 12 months.
Q3. What key milestones should a biotech startup achieve before seeking Series A funding? Before seeking Series A funding, biotech startups should complete preclinical toxicology studies, have a defined manufacturing strategy, prepare regulatory documentation, demonstrate market validation through partnerships or early revenue, and secure strong IP protection.
Q4. How should biotech founders prepare for the due diligence process in Series A fundraising? To prepare for due diligence, founders should organize comprehensive documentation including formation records, material contracts, financial statements, and employment agreements in an electronic data room. For biotech companies, detailed clinical data packages are particularly important.
Q5. What’s the recommended timeline for building relationships with potential Series A investors? It’s advisable to start building relationships with potential Series A investors at least 6-9 months before needing capital. This extended timeline is crucial given that securing funding often requires hundreds of investor conversations and extensive due diligence.
